Manage your formulary budget
Proactively manage your pharmacy inventory
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Pharmaceutical compositions of cisplatin|
|Abstract:||A stable, sterile aqueous solution of cisplatin in a sealed container such as an ampul or vial in unit dosage form suitable for intravenous administration to man is provided which has a concentration of cisplatin between about 0.1 and about 1.0 mgm./ml. and a pH in the range of 2.0 to 3.0 or preferably about 2.5. It can also contain sodium chloride and mannitol.|
|Inventor(s):||Granatek; Edmund S. (Syracuse, NY), Ziemba; Gerald M. (Bridgeport, NY), Grab; Frederick L. (Fayetteville, NY)|
|Assignee:||Bristol-Myers Company (New York, NY)|
Patent Claim Types:|
see list of patent claims
|Formulation; Dosage form; Composition;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Argentina||218134||<disabled in preview>|
|Austria||A164879||<disabled in preview>|
|Austria||362052||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.